Literature DB >> 26972858

Justifying vein resection with pancreatoduodenectomy.

Savio G Barreto1, John A Windsor2.   

Abstract

Interest in radical surgery to achieve complete resection and improve long-term survival in patients undergoing pancreatoduodenectomy for ductal adenocarcinoma has been renewed. This surgery includes extended lymphadenectomy, multivisceral resections, and synchronous arterial and venous resections. The evidence that these surgeries improve long-term survival is poor, except perhaps for synchronous venous resection, which can be justified if a margin negative (R0) resection is achieved without increased morbidity and mortality, and if there is no invasion of the vein wall. The recognition of patients with borderline resectable pancreatic cancer and the increasing use of neoadjuvant treatment makes it more difficult to know if the vein is invaded, increases reliance on trial dissection to establish resectability, and might increase the number of synchronous venous resections done. This Personal View seeks to review the justification for pancreatoduodenectomy with synchronous venous resection to promote debate and draw attention to the gaps in knowledge for further research.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26972858     DOI: 10.1016/S1470-2045(15)00463-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  15 in total

Review 1.  [Pancreatic ductal adenocarcinoma].

Authors:  E Gallmeier; T M Gress
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

2.  The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future?

Authors:  John A Windsor; Savio George Barreto
Journal:  J Gastrointest Oncol       Date:  2017-02

3.  Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer.

Authors:  Masaru Miyazaki; Hideyuki Yoshitomi; Shigetsugu Takano; Hiroaki Shimizu; Atsushi Kato; Hiroyuki Yoshidome; Katunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Daisuke Suzuki; Nozomu Sakai; Masayuki Ohtuka
Journal:  Langenbecks Arch Surg       Date:  2017-03-30       Impact factor: 3.445

4.  Pancreatectomy with Hepatic Artery Resection for Pancreatic Head Cancer.

Authors:  Feng Yang; Xiaoyi Wang; Chen Jin; Hang He; Deliang Fu
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

5.  Pancreatic ductal adenocarcinoma with inferior vena cava invasion: a report of three resected cases.

Authors:  Takuya Mizumoto; Tadahiro Goto; Hirochika Toyama; Keitaro Sofue; Sadaki Asari; Sachio Terai; Motofumi Tanaka; Masahiro Kido; Tetsuo Ajiki; Takumi Fukumoto; Yonson Ku
Journal:  Surg Case Rep       Date:  2017-05-23

6.  Vein resection in patients with adenocarcinoma of the head of pancreas adherent to the portomesenteric venous axis is beneficial despite a high rate of R1 resection.

Authors:  Ramkiran Cherukuru; Sanjay Govil; Mukul Vij; Mohamed Rela
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-08-31

7.  Laparoscopic pancreatoduodenectomy combined with portal-superior mesenteric vein resection and reconstruction with interposition graft: Case series.

Authors:  Xin Wang; Yunqiang Cai; Wei Zhao; Pan Gao; Yongbin Li; Xubao Liu; Bing Peng
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

Review 8.  Optimizing the outcomes of pancreatic cancer surgery.

Authors:  Oliver Strobel; John Neoptolemos; Dirk Jäger; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

Review 9.  Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy.

Authors:  Danko Mikulic; Anna Mrzljak
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

10.  The Utility of Preoperative Vascular Grading in Patients Undergoing Surgery First for Pancreatic Cancer: Does Radiologic Arterial or Venous Involvement Predict Pathologic Margin Status?

Authors:  Neha Goel; Jimson W D'Souza; Karen J Ruth; Barton Milestone; Andreas Karachristos; Rajeswari Nagarathinam; Harry Cooper; John Hoffman; Sanjay Reddy
Journal:  J Oncol       Date:  2018-08-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.